In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $17.55 in the prior trading day, Bicara Therapeutics Inc (NASDAQ: BCAX) closed at $17.27, down -1.60%. In other words, the price has decreased by -$1.60 from its previous closing price. On the day, 0.22 million shares were traded. BCAX stock price reached its highest trading level at $17.79 during the session, while it also had its lowest trading level at $17.246.
Ratios:
Our goal is to gain a better understanding of BCAX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.14 and its Current Ratio is at 14.14. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on December 18, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On August 19, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $36.
Wells Fargo Upgraded its Underweight to Equal Weight on May 23, 2025, while the target price for the stock was maintained at $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when Hyep Ivan sold 9,200 shares for $18.31 per share. The transaction valued at 168,492 led to the insider holds 145,355 shares of the business.
Hyep Ivan bought 9,200 shares of BCAX for $164,404 on Dec 22 ’25. On Dec 15 ’25, another insider, Cohlhepp Ryan, who serves as the President and COO of the company, sold 12,500 shares for $18.68 each. As a result, the insider received 233,548 and left with 189,141 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 946084352 and an Enterprise Value of 657892288.
Stock Price History:
The Beta on a monthly basis for BCAX is -0.85, which has changed by -0.08211297 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, BCAX has reached a high of $19.75, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is 1.54%, while the 200-Day Moving Average is calculated to be 29.59%.
Shares Statistics:
The stock has traded on average 754.00K shares per day over the past 3-months and 899490 shares per day over the last 10 days, according to various share statistics. A total of 54.61M shares are outstanding, with a floating share count of 32.04M. Insiders hold about 41.51% of the company’s shares, while institutions hold 63.95% stake in the company. Shares short for BCAX as of 1764288000 were 7655080 with a Short Ratio of 10.63, compared to 1761868800 on 6457982. Therefore, it implies a Short% of Shares Outstanding of 7655080 and a Short% of Float of 21.82.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Bicara Therapeutics Inc (BCAX).The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.58 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.34 and -$2.58 for the fiscal current year, implying an average EPS of -$2.49. EPS for the following year is -$2.95, with 8.0 analysts recommending between -$2.31 and -$3.4.
